Лотемакс

Country: Iżrael

Lingwa: Russu

Sors: Ministry of Health

Ingredjent attiv:

LOTEPREDNOL ETABONATE 5 MG / 1 ML

Disponibbli minn:

SALOMON,LEVIN & ELSTEIN LTD

Kodiċi ATC:

S01BA14

Għamla farmaċewtika:

OPHTHALMIC SUSPENSION

Rotta amministrattiva:

OCULAR

Manifatturat minn:

BAUSCH & LOMB INCORPORATED, USA

Grupp terapewtiku:

LOTEPREDNOL

Indikazzjonijiet terapewtiċi:

Lotemax is indicated for the treatment of steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitides, when the inherent hazard of steroid use is accepted to otain an advisable diminution in edema and inflammation. Lotemax is less effective than prednisolone acetate 1 % in two 28 day controlled clinical studies in acute anterior uveitis, where 72 % of patients treated with Lotemax experienced resolution of anterior chamber cells, compared to 87 % of patients treated with prednisolone acetate 1 % . The incidence of patients with clinically significant increases in IOP (> or = 10 mmHg) was 1 % with Lotemax adn 6 % with prednisolone acetate 1 %. Lotemax should not be used in patients who require a more potent corticosteroid for this indication. Lotemax is also indicated for the treatment of po

Data ta 'l-awtorizzazzjoni:

2009-11-01